

CURRICULUM VITAE

JOHN M. ROBERTSON, M.D.

EDUCATION

- 1977 - 1981 Undergraduate: University of Michigan, Ann Arbor, Michigan, B.S.
with High Distinction
- 1981 - 1985 Graduate: University of Michigan, Ann Arbor, Michigan, M.D.

POSTDOCTORAL TRAINING

- 1985 - 1986 Internship: William Beaumont Hospital, Royal Oak, Michigan
- 1986 - 1989 Residency: William Beaumont Hospital, Royal Oak, Michigan -
Radiation Oncology
- 1988 - 1989 Chief Resident: William Beaumont Hospital, Royal Oak, Michigan -
Radiation Oncology

ACADEMIC APPOINTMENTS

- 1989 - 1990 Lecturer, Department of Radiation Oncology, University of Michigan
Medical Center, Ann Arbor, Michigan
- 1990 - 1994 Instructor, Department of Radiation Oncology, University of Michigan
Medical Center, Ann Arbor, Michigan
- 1994 - 1995 Assistant Professor, Department of Radiation Oncology, University of
Michigan Medical Center, Ann Arbor, Michigan
- 2009 - 2010 Clinical Associate Professor, Department of Radiation Oncology, Oakland
University William Beaumont School of Medicine.
- 2010 - Professor, Department of Radiation Oncology, Oakland University
William Beaumont School of Medicine.

HOSPITAL APPOINTMENTS

- 1996 - 2014 Director of Clinical Research, Radiation Oncology, William Beaumont
Hospital, Royal Oak, Michigan
- 2004 – present Vice Chair, Radiation Oncology, William Beaumont Hospital, Royal Oak,
Michigan
- 2011 – 2019 Principal Investigator, Beaumont Community Clinical Oncology Program,
NCORP Beaumont Health System
- 2011 – 2013 Interim Health System Chair, Beaumont Hospital Health System, Royal
Oak, Michigan

GRANT SUPPORT

American Society of Clinical Oncology, Clinical Research Career
Development Award, “Two Phase I trials of BrdUrd and radiation therapy
for locally advanced gynecologic and rectal cancer” 7/92 - 6/96 (\$50,000
direct cost annually).

CERTIFICATION AND LICENSURE

Medical Licensure: State of Michigan
Board Certification: American Board of Radiology, Radiation Oncology,
1990.

HONORS AND AWARDS

1978 - 1981 James B. Angell Scholar, University of Michigan
1981 Phi Beta Kappa
1985 Roger A. Berg Prize for Excellence in Radiology
1992 - 1996 ASCO Clinical Research Career Development Award
2007 Outstanding Teacher Award
2009 - 2018 Best Doctors in America
2013 - 2021 Castle Connolly Regional Top Doctor

MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES

American Society for Radiation Oncology, 1991
American Society of Clinical Oncology, 1992

TEACHING ACTIVITIES

1990 - 1995 Radiation Therapy Technology Training Program, University of Michigan
Medical Center
1990 - 1995 Radiation Oncology Residency Training Program, University of Michigan
Medical Center
1996 - present Radiation Oncology Residency Training Program, William Beaumont
Hospital

EXTRAMURAL INVITED PRESENTATIONS

“Kidney Dose With Axial vs Non-Axial Pancreatic Radiotherapy: A Dose
Volume Histogram Comparison,” American Society for Therapeutic Radiology
and Oncology, Miami Beach, Florida, October 15 - 19, 1990.

“Intra-Abdominal 3-D Treatment Planning: A Physician's Perspective,”
AAPM/AAMD spring meeting, Seattle, Washington, March 14 - 16, 1991.

“Pancreatic Cancer,” Michigan Tumor Registrar Association, Ann Arbor,
Michigan, May 11, 1991.

“Adjuvant Pelvic Radiation Therapy in Patients With High-Risk Resected Rectal
Cancer and Metastatic Disease Confined to the Liver,” Radiologic Society of
North America, Chicago, Illinois, December 6 - 10, 1991.

“Filgrastim Support for Abdominal Field Radiation in Ovarian Cancer,” AMGEN
International Radiotherapy Workshop, Washington, D.C., June 25, 1992.

“The Use of 3-D Radiation Therapy and Intraarterial Hepatic FUdR for the Treatment of Liver Metastases,” Workshop on Three-Dimensional Treatment Planning, Geneva, Switzerland, October 19 - 21, 1992.

“The Treatment of Primary Hepatobiliary Cancers With External Beam Radiation Therapy and Intraarterial Hepatic Fluorodeoxyuridine,” American Society for Therapeutic Radiology and Oncology, San Diego, California, November, 9 - 13, 1992.

“Preoperative Radiation Therapy and Iododeoxyuridine for Large Retroperitoneal Sarcomas,” American Society for Therapeutic Radiology and Oncology, New Orleans, Louisiana, October 11 - 15, 1993.

“The Treatment of Colorectal Liver Metastases With Conformal Radiation Therapy and Regional Chemotherapy,” American Society for Therapeutic Radiology and Oncology, San Francisco, California, October 3 - 6, 1994.

“Long Term Results of Intraarterial Hepatic Fluorodeoxyuridine and Conformal Radiation Therapy for Hepatobiliary Tumors,” American Society of Clinical Oncology, Los Angeles, March 1995.

“A Phase I/II Study of Bromodeoxyuridine (BrdU) and Radiation Therapy (RT) for Locally Advanced Cervix Cancer,” American Society of Clinical Oncology, Los Angeles, March 1995.

“Continuous Infusional Bromodeoxyuridine and Radiation Therapy for Locally Advanced/Recurrent Carcinoma of the Cervix, Vagina and Endometrium,” Educational Symposium on Halogenated Pyrimidines, Miami Beach, Florida, October 8, 1995.

“Dose Escalation for Non-Small Cell Lung Cancer Using Conformal Radiation Therapy,” American Society for Therapeutic Radiology and Oncology, Miami Beach, Florida, October 10, 1995.

“The Treatment of Intrahepatic Tumors with Conformal Radiation Therapy,” American Society for Therapeutic Radiology and Oncology, Miami Beach, Florida, October 11, 1995.

“Clinical Experience with 3D Planning in the Treatment of Hepatic Tumors,” 3D Radiation Treatment Planning Congress, Munich, Germany, March 21 - 23, 1996.

“Clinical Experience with Dose Escalation for Non-Small Cell Lung Cancer Using Conformal Radiation Therapy,” 3D Radiation Treatment Planning Congress, Munich, Germany, March 21 - 23, 1996.

“A Phase I Trial of Hepatic Arterial Bromodeoxyuridine and Conformal Radiation Therapy for Patients with Hepatic Tumors,” American Society for Therapeutic Radiology and Oncology, Los Angeles, October 30, 1996.

“The Role of Radiation Therapy for Pancreas Cancer,” Michigan Tumor Registrars Association, Livonia, Michigan, June 5, 1997.

“Initial experience with Active Breathing Control of liver motion during ventilation”, American Society for Therapeutic Radiology and Oncology, Orlando, October 19-23, 1997.

“The Potential Role of IMRT for Rectal Cancer,” International Intensity Modulated Radiation Therapy Consortium, Elekta Oncology Systems, Gatwick, England, May 27, 1999.

“The Potential Role of Intensity Modulated Radiation Therapy (IMRT) for Rectal Cancer,” American Society for Therapeutic Radiology and Oncology, San Antonio, November 3, 1999.

“The Small Bowel Position During Adjuvant Radiation Therapy for Rectal Cancer,” American Society for Therapeutic Radiology and Oncology, Boston, October 25, 2000.

“Investigations in the use of IMRT for Rectal Cancer”, 27th Annual Meeting of the American Association of Medical Dosimetrists, Dearborn, Michigan, June 4, 2002.

“The dose-volume relationship of chronic small bowel toxicity from adjuvant pelvic radiation therapy and chemotherapy for rectal cancer, American Society for Therapeutic Radiology and Oncology, New Orleans, October 6-10, 2002.

“A phase I trial of hypofractionated intensity modulated radiation therapy with full dose gemcitabine for locally unresectable pancreas cancer”, The Radiological Society of North America, 90th Scientific Assembly and Annual Meeting, Chicago, November 28 – December 3, 2004.

“Radiation Therapy in the Treatment of Colorectal Cancer”, 3rd Annual Trisha Ehinger Radiation Oncology Conference, Grand Rapids, Michigan, May 3, 2005.

“Confirmation of the dose-volume relationship for acute small bowel toxicity during the treatment of rectal cancer”, American Society for Therapeutic Radiology and Oncology, Denver, October 16-20, 2005.

“Principal component analysis of small bowel dose volume histograms and acute diarrhea in the treatment of rectal cancer”, American Society for Therapeutic Radiology and Oncology, Philadelphia, November 5-9, 2006.

“Advanced treatment planning for Rectal Cancer”, University of North Carolina, Chapel Hill, NC, August 7, 2007.

“Predicting Grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff-dose logistic regression NTCP model”, American Society for Therapeutic Radiology and Oncology, Los Angeles, CA, October 28-November 1, 2007.

“Progress report on a Phase I trial of conformal radiation therapy with concurrent full dose gemcitabine and erlotinib for unresected pancreas cancer”, 2008 Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008.

“The relationship between chronic bowel dysfunction and the small bowel dose volume histogram of rectal cancer survivors”, American Society for Radiation Oncology, Miami Beach, FL, October 2 -6, 2011.

“Implementation of a patient experience focused review at the time of radiation therapy simulation”. ASCO Quality Care Symposium, Phoenix, AZ, September 28-29, 2018

“Patient satisfaction in radiation oncology”. American Society for Radiation Oncology, Chicago, IL, September 15-18, 2019.

COMMITTEE AND ADMINISTRATIVE SERVICE

National

- 1994 - 1995 National Cancer Institute, Member PDQ External Advisory Board
- 1994 - 2003 Radiation Therapy Quality Assurance Co-ordinator, Southwest Oncology Group, protocol 9304 (INT-0144)
- 1998 – 1999 Oral Board Examiner, Lung/Sarcoma, American Board of Radiology
- 2001 Oral Board Examiner, Gastrointestinal, American Board of Radiology
- 2001 - 2004 Member, Gastrointestinal Cancer Committee, Radiation Therapy Oncology Group
- 2004 - 2007 Information Technology Development and Resource Committee, American Society of Therapeutic Radiology and Oncology
- 2004 - 2007 Emerging Technologies Committee, American Society of Therapeutic Radiology and Oncology

William Beaumont Hospital

- 1999 - 2001 Colorectal Cancer Research Team Leader
- 1999 - 2001 Gastrointestinal Cancer Research Team Leader
- 1999 - 2001 Thoracic Oncology Research Team Member
- 2005 - 2013 Human Investigation Committee Member
- 2006 - Quality Assurance Committee, Department of Radiation Oncology
- 2006 - 2019 Radiation Oncology Committee Chair, CCOP
- 2009 - 2010 Investigator-Initiated Study Clinical Research Task Force member

2010 - 2015 Physician Service Excellence Task Force
 2010 - 2011 Vice-Chair, Human Investigation Committee
 2011 - 2013 Cancer Clinical Operations Board
 2011 - 2013 Medical Executive Board
 2011 - 2013 Hospital Executive Committee
 2011 - 2020 Chair, Protocol Review Committee, Beaumont CCOP/NCORP
 2011 - 2013 Chief Medical Officer Leadership Committee
 2011 - 2013 Council of Department and Program Chairs
 2019 Beaumont Medical Group Quality and Safety Committee

University of Michigan

1991 - 1995 University of Michigan Medical Center Quality Management Committee

BIBLIOGRAPHY

Completed Publications in Scientific Journals

Peer-Reviewed Publications

1. Rebner M, Gross BH, Robertson JM, Pennes DR, Spizarny OL, Glazer GM: CT evaluation of mediastinal masses. *Comput Radiol* 1987;11:103-110.
2. Robertson JM, Clarke DH, Matter RC: Breast conservation therapy: Severe breast fibrosis after radiotherapy in patients with collagen vascular disease. *Cancer* 1991;68:502-508.
3. Robertson JM, Marsh L, Ten Haken RK, Lawrence TS: The clinical application of a non-axial treatment plan for pancreatic and biliary malignancies. *Radiotherapy and Oncology* 1992;24:198-200.
4. Lawrence TS, Ten Haken RK, Kessler ML, Robertson JM, Lyman JT, LaVigne ML, DuRoss DJ, Brown MB, Andrews JC, Ensminger WK, Lichter AS: The use of 3-D dose volume analysis to predict radiation hepatitis. *Int J Radiat Oncol Biol Phys* 1992;23:781-788.
5. Lichter AS, Sandler HM, Robertson JM, Lawrence TS, Ten Haken RK, McShan DL, Fraass BA. Clinical experience with three-dimensional treatment planning. *Semin Rad Onc* 1992;2:257-266.
6. Lawrence TS, Kessler ML, Robertson JM: Conformal high dose radiation with intraarterial hepatic fluorodeoxyuridine: An alternative to surgical resection for patients with hepatic cancers. *Oncology* 1993;7:51-57.
7. Robertson JM, Lawrence TS, Dworzanin LM, Andrews JC, Walker S, Kessler ML, Ensminger WD: The treatment of primary hepatobiliary cancers with

- conformal radiation therapy and regional chemotherapy. *J Clin Oncol* 1993;11:1286-1293.
8. Ten Haken RK, Martel MK, Kessler ML, Hazuka MB, Lawrence TS, Robertson JM, Turrisi AT, Lichter AS: Use of Veff and iso-NTCP in the implementation of dose escalation protocols. *Int J Radiat Oncol Biol Phys* 1993;27:689-695.
 9. Marsh LH, Robertson JM, McShan DL: Simplified method for three-dimensional evaluation of interstitial brachytherapy applications. *Medical Dosim* 1994;19:203-210.
 10. Robertson JM, Kessler ML, Lawrence TS: Clinical results of three-dimensional conformal irradiation. *J Nat Cancer Inst* 1994;86:968-974.
 11. Robertson JM, Sondak VK, Weiss SA, Sussman JJ, Chang AE, Lawrence TS: Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas. *Int J Radiat Oncol Biol Phys* 1995;31:87-92.
 12. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WK, Fajardo LF: Hepatic toxicity resulting from cancer treatment. *Int J Radiat Oncol Biol Phys* 1995;31:1237-1248.
 13. Jackson A, Ten Haken RK, Robertson JM, Kessler ML, Kutcher GJ, Lawrence TS: Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. *Int J Radiat Oncol Biol Phys* 1995;31:883-891.
 14. Robertson JM, Lawrence TS, Walker S, Kessler ML, Andrews JC, Ensminger WD: The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy. *Int J Radiat Oncol Biol Phys* 1995;32:445-450.
 15. Yamasaki SA, Marn CS, Francis IR, Robertson JM, Lawrence TS: High-dose localized radiation therapy for treatment of hepatic malignant tumors: CT findings and their relation to radiation hepatitis. *Am J Roentgenol* 1995;165:79-84.
 16. Knol JA, Walker SC, Robertson JM, Yang Z, DeRemer S, Stetson PL, Ensminger WD, Lawrence TS: Incorporation of 5-Bromo-2'-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion. *Cancer Research* 1995;55:3687-3691.
 17. Pu AT, Robertson JM, Lawrence TS: Current status of radiation sensitization by fluoropyrimidines. *Oncology* 1995;9:707-714.

18. Robertson JM, Cha C, Andrews JC, Ensminger WD, Lawrence TS: Pelvic radiation therapy combined with hepatic artery chemotherapy for resected rectal carcinoma with liver metastases. *Int J Radiat Oncol Biol Phys* 1996;34:155-159.
19. Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ: A rationale for expanding the endpoints for clinical trials in advanced pancreatic cancer. *Cancer* 1996;78:627-632.
20. Robertson JM, Shewach DS, Lawrence TS: Preclinical studies of chemotherapy and radiation therapy for pancreatic cancer. *Cancer* 1996;78:674-679.
21. Balter JM, Ten Haken RK, Lawrence TS, Lam KL, Robertson JM: Uncertainties in CT-based radiation therapy treatment planning associated with patient breathing. *Int J Radiat Oncol Biol Phys* 1996;36:167-174.
22. Lawrence TS, Kessler ML, Robertson JM: 3-D conformal radiation therapy in upper gastrointestinal cancer. The University of Michigan experience. *Front Radiat Ther Oncol* 1996;29:221-8.
23. Watson B, Robertson JM, Marsh L, Martel MK, Lawrence T: A three-dimensional approach for re-irradiation of recurrent colorectal adenocarcinoma. *Med Dosim* 1996;21:79-82.
24. Robertson JM, Lawrence TS, Andrews JC, Walker S, Kessler ML, Ensminger WD: Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. *Int J Radiat Oncol Biol Phys* 1997;37:325-330.
25. Robertson JM, Ensminger WD, Walker S, Lawrence TS: A Phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer. *Int J Radiat Oncol Biol Phys* 1997;37:331-336.
26. Robertson JM, Turrisi AT, Hazuka MB, Martel MK, Ten Haken TK, Littles JF, Martinez FJ, Lichter AS: Dose escalation for non-small cell lung cancer using conformal radiation therapy. *Int J Radiat Oncol Biol Phys* 1997;37:1079-1085.
27. Ten Haken RK, Balter JM, Marsh LH, Robertson JM, Lawrence TS: Potential benefits of eliminating planning target volume expansions for patient breathing in the treatment of liver tumors. *Int J Radiat Oncol Biol Phys* 1997;38:613-617.
28. Robertson JM, McGinn CJ, Walker S, Marx MV, Kessler ML, Ensminger WD, Lawrence TS: A Phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases. *Int J Radiat Oncol Biol Phys* 1997;39:1087-1092.

29. Eisbruch A, Johnston CM, Martel MK, Robertson JM, Reynolds KR, Marsh LH, Roberts JA. Customized gynecologic interstitial implants: CT-based planning, dose evaluation and optimization aided by laparotomy. *Int J Radiat Oncol Biol Phys* 1998;40:1087-1093.
30. Sondak VK, Robertson JM, Sussman JJ, Saran PA, Chang AE, Lawrence TS. Preoperative idoxuridine and radiation for large soft tissue sarcomas: Clinical results with five-year follow-up. *Ann Surg Oncol* 1998;5:106-112.
31. McGinn CJ, Robertson JM, Lawrence TS, Marx MV, Walker S, Ensminger WD. A Phase I/II trial of chemoembolization with mitomycin C following hepatic arterial fluorodeoxyuridine/leucovorin and whole liver radiotherapy for patients with intrahepatic malignancies. *Cancer Therapeutics* 1998;1:89-95.
32. Fyles AW, Manchul L, Levin W, Robertson JM, Sturgeon J, Tsuji D. Effect of Filgrastim (G-CSF) during chemotherapy and abdomino-pelvic radiation therapy in patients with ovarian carcinoma. *Int J Radiat Oncol Biol Phys* 1998;41:843-847.
33. Eisbruch A, Robertson JM, Johnston CJ, Tworek J, Reynolds KR, Roberts JA, Lawrence TS. Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: A Phase I and drug incorporation study. *J Clin Oncol* 1999;17:31-40.
34. Wong JW, Sharpe MB, Jaffray DA, Kini VR, Robertson JM, Stromberg JS, Martinez AA. The use of Active Breathing Control (ABC) to reduce margin for breathing motion. *Int J Radiat Oncol Biol Phys* 1999;44:911-919.
35. Lacerna MD, Sharpe MB, Robertson JM. The effect of radiation on an ambulatory chemotherapy infusion pump. *Cancer* 1999;86:2150-3.
36. McGinn CJ, Zalupski MA, Shureiqi I, Robertson JM, et al. Phase I trial of radiation dose escalation with concurrent weekly full dose gemcitabine in patients with advanced pancreatic cancer. *J Clin Oncol* 2001;19:4202-8.
37. Nuyttens JJ, Robertson JM, Yan D, Martinez A. The position and volume of the small bowel during adjuvant radiation therapy for rectal cancer. *Int J Radiat Oncol Biol Phys* 2001;51:1271-1280.
38. Willett C, Ajani J, Kelsen D . . . Robertson JM, et al. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. *Int J Radiat Oncol Biol Phys* 2001;51(3 suppl 2):19-27.
39. Laub W, Yan D, Robertson J, Martinez A. Intensity modulated radiation therapy treatment (IMRT) in the radiotherapy treatment of colon-rectal cancer: the

- influence of profile smoothing on the efficiency of delivery. *J Radiother Practice* 2002;2:1-10.
40. Baglan KL, Frazier RC, Yan D, Huang RR, Martinez AA, Robertson JM. Dose-volume relationship of acute small bowel toxicity for chemoradiotherapy for patients with rectal cancer. *Int J Radiat Oncol Biol Phys* 2002;52:176-183.
 41. Nuyttens JJ, Robertson JM, Yan D, Martinez A. The variability of the clinical target volume for rectal cancer due to internal organ motion during adjuvant treatment. *Int J Radiat Oncol Biol Phys* 2002;53(2):497-503.
 42. Allen AM, Zalupski MM, Robertson JM, et al. Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose Gemcitabine. *Int J Radiat Oncol Biol Phys* 2004;59(5):1461-7.
 43. Nuyttens JJ, Robertson JM, Yan D, Martinez A. The influence of small bowel motion on conventional and intensity modulated radiation therapy (IMRT) for rectal cancer. *Cancer/Radiotherapie* 2004;8(5):297-304.
 44. Smalley SR, Benedetti JK, Williamson SK, Robertson JM, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. *J Clin Oncol* 2006;24(22):3542-3547.
 45. Robertson JM, Lockman D, Yan D, Wallace M. The dose-volume relationship of small bowel irradiation and acute grade three diarrhea during chemoradiotherapy for rectal cancer. *Int J Radiat Oncol Biol Phys* 2008;70(2):413-8.
 46. Robertson JM, Campbell JP, Yan D. Generic planning target margin for rectal cancer treatment setup variation. *Int J Radiat Oncol Biol Phys* 2009;74(5):1470-1475.
 47. Robertson JM, Söhn M, Yan D. Predicting grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff-dose logistic regression normal tissue complication probability model. *Int J Radiat Oncol Biol Phys*, 2010;77(1):66-72.
 48. Suen AW, Galoforo S, Marples B, McGonagle M, Downing L, Martinez AA, Robertson JM, Wilson GD. Sorafenib and radiation: A promising combination in colorectal cancer. *Int J Radiat Oncol Biol Phys*, 2010;78(1):213-220.
 49. Lanni TB Jr, Grills IS, Kestin LL, Robertson JM. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small cell lung cancer. *Am J Clin Oncol*, 2011;34:494-8.

50. Jury RP, Nadeau L, Wasvery H, Levine R, Robertson J. Implementing a Multidisciplinary Open Access Clinic at a Private Practice Based Community Hospital. *J Onc Practice*, 2010;6(6):e38.
51. Robertson JM, Margolis J, Jury RP, et al. A phase I study of conformal radiation therapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreas cancer. *Int J Radiat Oncol Biol Phys* 2012;82:e187-92.
52. Park S, Chunta JL, Robertson JM, et al. MicroPET/CT imaging of an orthotopic model of human glioblastoma multiforme and evaluation of pulsed low dose irradiation. *Int J Radiat Oncol Biol Phys* 2011 80:885-92.
53. Huang J, Robertson JM, Margolis J, et al. Long-Term Results of Full-Dose Gemcitabine with Radiation Therapy Compared to 5-Fluorouracil with Radiation Therapy for Locally Advanced Pancreas Cancer. *Radiother Oncol*, 2011;99:114-119.
54. Huang J, Robertson JM, Ye H, et al. Dose volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2012;83:1120-5.
55. Baschnagel AM, Mangona VS, Robertson JM, et al. Lung metastases treated with image-guided stereotactic body radiation therapy. *Clin Oncol (R Coll Radiol)* 2013;25:236-41.
56. Baschnagel A, Shah C, Margolis J, Nadeau L, Stein J, Jury R, Robertson JM. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine. *Int J Radiat Oncol Biol Phys* 2012;83:e331-5.
57. Russell MM, Ganz PA, Lopa S, Yothers G, Ko C, Arora A, Atkins JN, Bahary N, Soori G, Robertson J, et al. Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: Patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project R-04. *Ann Surg* 2015;261:144-148.
58. O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori G, Eakle J, Robertson JM, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: Surgical end points from National Surgical Adjuvant Breast and Bowel Project Trial R-04. *J Clin Oncol* 2014; 32:1927-1934.
59. Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, et al. Neoadjuvant 5-FU or capecitabine plus radiation with or

- without oxaliplatin in rectal cancer patients: A Phase III randomized clinical trial. *J Natl Cancer Inst* 2015; 107(11) pii: djv248. doi: 10.1093/jnci/djv248.
60. Mangona VS, Aneese AM, Marina O, Hymas RV, Ionascu D, Robertson JM, et al. Toxicity after central versus peripheral lung stereotactic body radiation therapy: A propensity score matched-pair analysis. *Int J Radiat Oncol Biol Phys* 2015; 91:124-32.
 61. Vu C, Lanni T, Robertson JM. Variations in Medicare Reimbursement in Radiation Oncology: An Analysis of the Medicare Provider Utilization and Payment Dataset. *Int J Radiat Oncol Biol Phys* 2016 94:1000-5.
 62. Rakhra S, Strauss JB, Robertson J, et al. Hypofractionated conformal radiotherapy with concurrent full-dose gemcitabine versus standard fractionation radiotherapy with concurrent fluorouracil for unresectable pancreatic cancer: a multi-institution experience. *J Gastrointestinal Cancer* 2016; 47:196-201.
 63. Johnson MD, Stone B, Thibodeau BJ, Baschnagel AM, Galoforo S, Fortier LE, Ketelsen B, Ahmed S, Kelley Z, Hana A, Wilson TG, Robertson JM, et al. The significance of Trk receptors in pancreatic cancer. *Tumor Biol* 2017; 39(2):1010428317692256
 64. Greenlee H, Lew DL, Hershman DL, Newman VA, Hanson L, Hartman SJ, Korner J, Shi Z, Molmenti CS, Sayegh A, Fehrenbacher L, Lo S, Klemp J, Rinn K, Robertson JM, et al. Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008). *Obesity* 2018;26:1539-49.
 65. Sura K, Ye H, Vu CC, Robertson JM, Kabolizadeh P. How many lymph nodes are enough? Defining the extent of lymph node dissection in stage I-III gastric cancer using the National Cancer Database. *J Gastrointest Oncol* 2018;9:1168-75.
 66. David J, Gresham G, Jabbour S, Deek M, Thomassian S, Robertson JM, et al. Neoadjuvant PET and MRI-based Intensity Modulated Radiotherapy Leads to Less Toxicity and Improved Pathologic Response Rates in Locally Advanced Rectal Cancer. *J Gastroint Oncol* 2018;9:641-9.
 67. Arden JD, Robertson JM, Rutka E, Ye H. A personalized patient teaching session at the time of radiation simulation may improve patient satisfaction scores. *Advances in Radiation Oncology* (in press).
 68. Parzen JS, Vayntraub A, Squires B, Almahariq MF, Thompson AB, Robertson JM, et al. A population-based analysis of chemoradiation versus radiation alone in the definitive treatment of patients with stage I-II squamous cell carcinoma of the anus. *J Gastrointest Onc* (in press).

1. Robertson JM, Clarke DH, Martinez A: The role of radiation therapy in high risk breast cancer. In: J Ragaz, IM Ariel (eds): High Risk Breast Cancer Therapy, (Springer-Verlag, Heidelberg, 1991), 141-159.
2. Blatt J, Neigut D, Robertson JM, Lawrence TS: Late effects: gastrointestinal/hepatic. In: LS Constine, W Hobbie, C Schwartz (eds): Evaluation and Management of the Childhood Cancer Survivor (Mosby, St. Louis, 1994), 197-211.
3. Nostrant TT, Robertson JM, Lawrence TS: Radiation and the gastrointestinal tract. In: Yamada T (ed): Textbook of Gastroenterology, second edition, (J.B. Lippincott, Philadelphia, 1995), 2524-2535.
4. Lawrence TS, Kessler JL, Robertson JM: 3-D Conformal Radiation Therapy in Upper Gastrointestinal Cancer: The University of Michigan Experience. In: Meyers JL, Purdy JA (eds): 3-D Conformal Radiotherapy; Front. Radiat. Ther. Oncol. (vol 29); (Karger, Basel, Switzerland, 1996), 221-228.
5. Robertson JM, Lawrence TS: Hepatobiliary Tumors. In: Tepper J, Gunderson L (eds), Clinical Radiation Oncology (Churchill-Livingstone, New York, 1999), 707-718.
6. Robertson JM, Lawrence TS: Radiation Therapy for Liver Tumors. In: Clavien P-A (ed), Primary and Secondary Liver Tumors: Current and Emerging Therapies (Blackwell Science, Malden, Massachusetts, 1999), 96-104.
7. Wagman L, Hoff PM, Robertson JM, Dwivedy S: Liver, gallbladder, and biliary tract cancers. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD (eds), Cancer Management: A Multidisciplinary Approach, 4th edition (PRR, Melville, NY, 1999), 255-271.
8. Robertson JM: Radiation Therapy for Hepatic Metastases. In: Saltz L (ed), Colorectal Cancer: Multimodality Management (Humana Press, Totowa, NJ, 2002), 233-243.
9. Wagman L, Robertson JM, Venook AP, O'Neil B, Hoff PM: Liver, gallbladder, and biliary tract cancers. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD (eds), Cancer Management: A Multidisciplinary Approach, 5th edition (PRR, Melville, NY, 2001), 255-272.
10. Wagman L, Robertson JM, O'Neil B, Venook AP: Liver, gallbladder, and biliary tract cancers. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD (eds), Cancer Management: A Multidisciplinary Approach, 6th edition (PRR, Melville, NY, 2002), 277-294.

11. Wagman LD, Robertson JM, O'Neil B: Liver, gallbladder, and biliary tract cancers. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD (eds), *Cancer Management: A Multidisciplinary Approach*, 7th edition (PRR, Melville, NY, 2003), 303-322.
12. Wagman LD, Robertson JM, O'Neil B: Liver, gallbladder, and biliary tract cancers. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD (eds), *Cancer Management: A Multidisciplinary Approach*, 8th edition (PRR, Melville, NY, 2004), 303-322.
13. Wagman LD, Robertson JM, O'Neil B: Liver, gallbladder, and biliary tract cancers. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD (eds), *Cancer Management: A Multidisciplinary Approach*, 9th edition (PRR, Melville, NY, 2004), 323-342.
14. Wagman LD, Robertson JM, O'Neil B: Liver, gallbladder, and biliary tract cancers. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD (eds), *Cancer Management: A Multidisciplinary Approach*, 10th edition (PRR, Melville, NY, 2007), 319-338.
15. Robertson JM. The Role of Radiation Therapy in Colorectal Cancer. In: Cappell MS (ed), *Gastroenterology Clinics of North America, Colorectal Cancer: Screening, Surveillance and Prevention*, (W. B. Saunders, Philadelphia, Pennsylvania, 2008), 269-286.
16. Wagman LD, Robertson JM, O'Neil B: Liver, gallbladder, and biliary tract cancers. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD (eds), *Cancer Management: A Multidisciplinary Approach*, 11th edition (PRR, Melville, NY, 2008), 339-357.
17. Wagman LD, Robertson JM, Raftery L, O'Neil B: Liver, gallbladder, and biliary tract cancers. In: Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, (eds), *Cancer Management: A Multidisciplinary Approach*, 12th edition (UBM Medica, Norwalk, CT, 2010), 305-328.
18. Wagman LD, Robertson JM, Raftery L, O'Neil B: Liver, gallbladder, and biliary tract cancers. In: Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, (eds), *Cancer Management: A Multidisciplinary Approach*, 13th edition (UBM Medica, Norwalk, CT, 2010), 325-349.
19. Wilson GD, Robertson JM, Wasvary H, Thibodeau BJ: The Stem Cell Environment: Kinetics, Signaling and Markers. In: Ettarh R (ed), *Colorectal Cancer - From Prevention to Patient Care*, (InTech, 2012), 301-326.

Abstracts, Preliminary Communications, Panel Discussions

1. Robertson JM, Marsh L, Ten Haken RK, Lawrence TS: Kidney dose with axial vs. nonaxial pancreatic radiotherapy: A dose volume histogram comparison. *Int J Radiat Oncol Biol Phys* 19:192, 1990.
2. Robertson JM, Cha CC, Ensminger WD, Lawrence TS: Adjuvant pelvic radiation therapy in patients with high-risk resected rectal cancer and metastatic disease confined to the liver. *Radiology* 181:111, 1991.
3. Robertson JM, Lawrence TS, Dworzanin LM, et al. The use of 3-D radiation therapy and intraarterial hepatic FUdR for the treatment of liver metastases. Workshop on Three-Dimensional Treatment Planning, Geneva, Switzerland, October 19-21, 1992.
4. Robertson JM, Lawrence TS, Dworzanin LM, et al. The treatment of primary hepatobiliary cancers with external beam radiation therapy and intraarterial hepatic fluorodeoxyuridine. *Int J Radiat Oncol Biol Phys* 24:151, 1992.
5. Robertson JM, Sondak VK, Weiss SA, et al. Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas. *Int J Radiat Oncol Biol Phys* 27:155, 1993.
6. Panel Discussion: The importance of symptom benefit and quality of life in pancreatic cancer. July 8, 1994, Newport, R.I.
7. Robertson JM, Lawrence TS, Walker S, et al. The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy. *Int J Radiat Oncol Biol Phys* 30:178, 1994.
8. Balter JM, Ten Haken RK, Lam K, Lawrence TS, Robertson JM, Turrisi AT. The use of spiral CT and spirometry to reduce uncertainties in treatment planning associated with breathing. *Int J Radiat Oncol Biol Phys* 30(suppl1):241-242, 1994.
9. Sondak VK, Hain JM, Robertson JM, et al. Preoperative radiation and iododeoxyuridine for extremity, head and neck, and mediastinal sarcomas. *Proc Am Soc Clin Oncol* 13:477, 1994.
10. Ten Haken RK, Balter JM, Lam KL, Robertson JM. Effects of patient breathing on CT-based 3-D planning for lung irradiation. *Med Phys* 21:914, 1994.
11. Robertson JM, Johnston C, Eisbruch A, et al. A phase I/II study of bromodeoxyuridine (BrdU) and radiation therapy (RT) for locally advanced cervix cancer. *Proc Am Soc Clin Oncol*, 14:201, 1995.

12. Lawrence TS, Robertson J, Andrews J, et al. Long term results of intraarterial hepatic fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary tumors. *Proc Am Soc Clin Oncol*, 14:199, 1995.
13. Robertson JM, Turrisi AT, Hazuka MB, et al. Dose escalation for non-small cell lung cancer using conformal radiation therapy. *Int J Radiat Oncol Biol Phys* 32(suppl 1):197, 1995.
14. Ten Haken RK, Balter JM, Marsh LH, Robertson JM, Lawrence TS. Potential benefits of gating conformal irradiation of liver tumors to the ventilatory cycle. *Int J Radiat Oncol Biol Phys* 32(suppl 1):187, 1995.
15. Robertson JM, Lawrence TS. Radiation therapy for intrahepatic cancers. American Society for Therapeutic Radiology, 37th Annual Meeting, Miami Beach, 1995.
16. Robertson JM, Ensminger WD, Walker SC, et al. A Phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with hepatic tumors. *Int J Radiat Oncol Biol Phys* 36(suppl 1): 212, 1996.
17. Robertson JM, Sharpe MB, Jaffray DA, Wong JW. Initial experience with Active Breathing Control of liver motion during ventilation. *Int J Radiat Oncol Biol Phys* 39(suppl):282, 1997.
18. Lacerna MD, Sharpe MB, Robertson JM: Radiation tolerance and mode of failure of a chemotherapy ambulatory infusion pump. *Int J Radiat Oncol Biol Phys* 39(suppl): 283, 1997.
19. McGinn CJ, Robertson JM, Ensminger WD, et al. A Phase I/II trial of chemoembolization with mitomycin C following hepatic arterial fluorodeoxyuridine/leucovorin and whole liver radiotherapy for patients with intrahepatic malignancies. *Int J Radiat Oncol Biol Phys* 39(suppl):159, 1997.
20. Pu AT, Harrison AS, Robertson JM, et al. The toxicity of elective nodal irradiation in the definitive treatment of non-small cell carcinoma of the lung. *Int J Radiat Oncol Biol Phys* 39(suppl):196, 1997.
21. Eisbruch A, Robertson JM, Johnston DM, et al. Radiation (RT) alternating with bromodeoxyuridine (BU) for advanced cervix cancer: A Phase I/II trial and drug incorporation study. *Int J Radiat Oncol Biol Phys* 42(suppl):148, 1998.
22. Kini VR, Sharpe MB, Jaffray DA, Robertson JM, Wong JW. Potential for dose escalation in the radiotherapy of hepatic tumors using active breathing control (ABC): A planning study. *Int J Radiat Oncol Biol Phys* 42(suppl):141, 1998.

23. Sharpe MB, Yan D, Jaffray DA, Wu Y, Miller BM, Brabbins DS, Robertson JM, et al. A comprehensive process for the clinical implementation of intensity-modulated radiotherapy. *Int J Radiat Oncol Biol Phys* 42(suppl):365, 1998.
24. McGinn CJ, Shureiqi I, Robertson JM, et al. A Phase I trial of radiation dose escalation with full dose gemcitabine (GEM) in patients (pts) with pancreatic cancer. *Proc ASCO* 18:274a, 1999.
25. Robertson JM, Yan D, Girimonte PE, Kota K. The potential benefit of intensity modulated radiation therapy (IMRT) for rectal cancer. *Int J Radiat Oncol Biol Phys* 45(suppl):248, 1999.
26. Nuyttens JJ, Robertson JM, Yan D, Martinez AA. The influence of small bowel motion on intensity modulated radiation therapy (IMRT) for rectal cancer. *Int J Radiat Oncol Biol Phys* 48(suppl):168, 2000.
27. McGinn CJ, Shureiqi I, Robertson JM, et al. Encouraging survival data from a phase I trial of radiation (RT) dose escalation with full dose gemcitabine (GEM) in patients with unresectable pancreatic cancer. *Int J Radiat Oncol Biol Phys* 48(suppl):223, 2000.
28. Baglan KL, Robertson JM, Frazier RC, et al. A CT-based analysis of the relationship between acute grade 3 small bowel toxicity and the volume of small bowel irradiated in patients receiving concurrent chemoradiotherapy for rectal cancer. *Int J Radiat Oncol Biol Phys* 48(suppl):224, 2000.
29. Nuyttens JJ, Robertson JM, Yan D, Martinez AA. The small bowel position during adjuvant radiation therapy for rectal cancer. *Int J Radiat Oncol Biol Phys* 48(suppl):226, 2000.
30. McGinn, Zalupski MM, Shureiqi I, Robertson JM, et al. Final report of a Phase I trial of radiation (RT) dose escalation with concurrent weekly full dose gemcitabine (GEM) in advanced pancreatic cancer. *Proc ASCO* 20:153, 2001.
31. Allen AM, Zalupski MM, Eckhauser FE, Robertson JR, et al. A phase I trial of radiation (RT) dose escalation with concurrent full dose gemcitabine (GEM) following resection of pancreatic cancer. *Proc ASCO* 21:138, 2002.
32. Robertson JM, Baglan KL, Hardy MM, et al. The dose-volume relationship of chronic small bowel toxicity from adjuvant pelvic radiation therapy and chemotherapy for rectal cancer. *Int J Radiat Oncol Biol Phys* 54(2 Suppl):209, 2002.
33. Smalley SR, Benedetti J, Williamson S, Robertson J, et al. Intergroup 0144 – phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion

- (PVI) before and after XRT + PVI vs bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV. Proc ASCO 22:251, 2003.
34. Smalley SR, Benedetti J, Williamson S, Robertson J, et al. Intergroup 0144 A Phase III rectal surgical adjuvant study of pelvic radiation (XRT) plus 5-FU based chemotherapy (bolus 5-FU before and after PVI + XRT vs PVI before, during, and after XRT vs biochemically modulated bolus 5-FU and XRT): Mature outcome results and pelvic failure analysis. Int J Radiat Oncol Biol Phys 60(1 suppl):S137, 2004.
 35. Robertson JM, Lockman DM, Yan D, et al. Confirmation of the dose-volume relationship for acute small bowel toxicity during the treatment of rectal cancer. Int J Radiat Oncol Biol Phys 63(1 suppl):S165, 2005.
 36. Burgess L, Zhang T, Liang J, Wu Q, Robertson J, Yan D. Image guided radiotherapy by online plan re-optimization: Studies of dosimetric benefits by treatment simulations. Int J Radiat Oncol Biol Phys 66(suppl):S629, 2006.
 37. Hardy MM, Robertson JM, Calcaterra A, Wallace M. A quality of life assessment of genitourinary and sexual function of patients diagnosed with prostate cancer undergoing various radiation treatment modalities. Int J Radiat Oncol Biol Phys 66(suppl):S371, 2006.
 38. Robertson JM, Soehn M, Yan D. Principal component analysis of small bowel dose volume histograms and acute diarrhea in the treatment of rectal cancer. Int J Radiat Oncol Biol Phys 66(suppl):S301, 2006.
 39. Burgess L, Zhang T, Liang J, Wu Q, Robertson J, Yan D. Image guided radiotherapy by online plan re-optimization: Studies of dosimetric benefits by treatment simulations. Int J Radiat Oncol Biol Phys 66(suppl):S629, 2006.
 40. Robertson JM, Soehn M, Yan D. Predicting Grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff-dose logistic regression NTCP model. Int J Radiat Oncol Biol Phys 69(suppl):S268, 2007.
 41. Hardy MM, Robertson JM, Balasubramaniam M. Determinants of the overall urinary quality of life in patients treated with radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 69(suppl):S580, 2007.
 42. Galerani AP, Kestin LL, Grills IS, Chao KK, Suen AW, Falkowski J, Lala V, Martinez AA, Robertson JM. The value of endoscopic ultrasound (EUS) and positron emission tomography (PET) in predicting outcome following combined modality treatment for esophageal cancer. Int J Radiat Oncol Biol Phys 69(suppl):S285, 2007.

43. Campbell JP, Robertson J, Yan D. Generalized planning target margin for rectal cancer treatment based on interfraction setup variation. *Int J Radiat Oncol Biol Phys* 69(suppl):S299, 2007.
44. Robertson JM, Hardy MM, Ballouz S, et al. Progress report on a Phase I trial of conformal radiation therapy with concurrent full dose gemcitabine and erlotinib for unresected pancreas cancer, 2008 Gastrointestinal Cancers Symposium, pg 192, 2008.
45. Smalley S, Rankin C, Benedetti J, Williamson S, Robertson J, et al. Pelvic failure analysis in INT 0144: Evaluation of chemotherapy regimen, risk group stratification, and nodal count. *Int J Radiat Oncol Biol Phys* 72(suppl):S70, 2008.
46. Robertson JM, Hardy MM, Ballouz S, et al. Conformal radiation therapy with concurrent full-dose gemcitabine and erlotinib for unresected pancreas cancer: A phase I trial. *Int J Radiat Oncol Biol Phys* 72(suppl):S275, 2008.
47. Robertson J, Ballouz S, Jaiyesimi, et al. A Phase I study of dose escalating conformal radiation therapy with concurrent full-dose gemcitabine and erlotinib for unresected pancreas cancer. *Int J Radiat Oncol Biol Phys* 75 (suppl):S270, 2009.
48. Suen AW, Galoforo S, Marples B, Robertson JM, Wilson GD. Synergy of sorafenib and radiation in colorectal and pancreatic cancer. *Int J Radiat Oncol Biol Phys* 75 (suppl):S68, 2009.
49. Lanni TB, Grills IS, Kestin LL, Marvin KS, Robertson JM, et al. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small cell lung cancer. *Int J Radiat Oncol Biol Phys* 75 (suppl):S444, 2009.
50. Huang J, Robertson J, Margolis J, et al. Improved survival with involved field radiotherapy and concurrent full dose gemcitabine for unresectable pancreatic adenocarcinoma – The eleven year Beaumont experience. *Int J Radiat Oncol Biol Phys* 78 (suppl):S102, 2010.
51. Mislamani M, Grills IS, Robertson JM, et al. Stereotactic lung radiotherapy (SBRT) associated with improved local control compared to 3-dimensional conformal radiotherapy (3DCRT) for stage I non-small cell lung cancer (NSCLC). *Int J Radiat Oncol Biol Phys* 78 (suppl):S512, 2010.
52. Baschnagel A, Mangona VS, Robertson J, et al. Lung metastases treated with image-guided stereotactic radiation therapy. *Int J Radiat Oncol Biol Phys* 78 (suppl):S529, 2010.

53. Robertson J, Balasubramaniam M, Calcaterra A, et al. The role of specific urinary complaints in determining the overall urinary quality of life in patients treated with radiation therapy for prostate cancer. *Int J Radiat Oncol Biol Phys* 78 (suppl):S603, 2010.
54. Robertson J, Ye H, Wallace M, Burgess L. The relationship between chronic bowel dysfunction and the small bowel dose volume histogram of rectal cancer survivors. *Int J Radiat Oncol Biol Phys* 81 (suppl):S99, 2011.
55. Baschnagel AM, Shah C, Robertson J. Outcomes for resected pancreatic patients treated with chemoradiation with and without adjuvant chemotherapy. *Int J Radiat Oncol Biol Phys* 81 (suppl):S338, 2011.
56. Huang J, Robertson JM, Ye H, Yan D. Dose-volume analysis of predictors for gastrointestinal toxicity after radiotherapy and concurrent full-dose gemcitabine for locally advanced pancreatic adenocarcinoma. *Int J Radiat Oncol Biol Phys* 81 (suppl):S169, 2011
57. Patel R, Gentile M, Fowler AM, Marina O, Helenowski I, Sathiaselan, Robertson JM, Hayes JP, Small W. A multi-institutional retrospective study of radiation therapy parameters and outcomes in patients with gastroesophageal junction adenocarcinoma. *Int J Radiat Oncol Biol Phys* 87(suppl):S301, 2013.
58. Marina O, McAree DP, Watts J, Gustafson G, Costello D, Ye H, Robertson JM. Whole-mount pathologic evaluation of specimens following preoperative radiation therapy (RT) for rectal cancer identifies more lymph nodes and greater tumor (T) stage. *Int J Radiat Oncol Biol Phys* 87(suppl):S333, 2013
59. Zamdborg L, Lee KC, Harris A, Doo F, Gersten DB, Grills IS, Robertson J. Outcomes after neoadjuvant or definitive chemoradiation therapy for esophageal/gastroesophageal junction carcinoma. *Int J Radiat Oncol Biol Phys* 93(3); E180, 2015.
60. Bergsman AJ, Blas KG, Zamdborg L, Balde K, Wloch JL, Yan D, Robertson J. The influence of bladder volume on small bowel toxicity and posterior bladder position in patients undergoing chemoradiation for treatment of rectal cancer. *Int J Radiat Oncol Biol Phys* 96(2); E203, 2016.
61. Wang WGA, Sura K, Robertson J, et al. Outcomes and toxicity for treatment of adrenal metastases with radiation therapy. *Int J Radiat Oncol Biol Phys* 96(2); E273-E274, 2016.
62. Zamdborg L, Lee KC, Harris A, Doo F, Bazil T, Xu Y, Gersten DB, Grills IS, Robertson J, Stromberg JS. Predictors of esophageal stricture after definitive chemoradiation therapy for esophageal/gastroesophageal junction carcinoma. *Int J Radiat Oncol Biol Phys* 96(2); E150, 2016.

63. Robertson JM, Rutka E, Ye H. Implementation of a patient experience focused review at the time of radiation therapy simulation. ASCO Quality Care Symposium, Phoenix, AZ, September 28-29, 2018.
64. Ye H, Rutka E, Robertson J. Determination of the relative importance of different clinical domains on the overall patient satisfaction domain using structural equation modeling. *Int J Radiat Oncol Biol Phys* 102(3):e734, 2018.
65. Rutka E, Ye H, Robertson J. Factors related to patient satisfaction in Radiation Oncology. *Int J Radiat Oncol Biol Phys* 102(3):e732, 2018.
66. Thompson A, Quinn TJ, Thibodeau BJ, Douglas J, Peeples C, Cousineau C, Wasvary H, Robertson J, et al. Genomic analysis to predict response to neoadjuvant chemoradiation therapy in rectal cancer. *Int J Radiat Oncol Biol Phys*, 102(3):e174, 2018.
67. Robertson J, Rutka E, Ye H. Patient satisfaction in radiation oncology. *Int J Radiat Oncol Biol Phys*, 105:E590, 2019